Centessa Pharmaceuticals (NASDAQ:CNTA) Trading Down 5.3% After Insider Selling

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report)'s share price traded down 5.3% during mid-day trading on Monday following insider selling activity. The stock traded as low as $17.85 and last traded at $18.02. 142,969 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 617,110 shares. The stock had previously closed at $19.03.

Specifically, insider Karen M. Anderson sold 30,526 shares of Centessa Pharmaceuticals stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $19.03, for a total transaction of $580,909.78. Following the completion of the transaction, the insider now owns 54,322 shares in the company, valued at approximately $1,033,747.66. This trade represents a 35.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CTO Tia L. Bush sold 11,000 shares of Centessa Pharmaceuticals stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $16.86, for a total value of $185,460.00. Following the completion of the transaction, the chief technology officer now owns 121,503 shares of the company's stock, valued at approximately $2,048,540.58. This represents a 8.30 % decrease in their position. The disclosure for this sale can be found here. In related news, insider Karen M. Anderson sold 6,471 shares of Centessa Pharmaceuticals stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $16.86, for a total value of $109,101.06. Following the completion of the transaction, the insider now owns 54,322 shares in the company, valued at $915,868.92. The trade was a 10.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Wall Street Analyst Weigh In

A number of research analysts recently commented on CNTA shares. Guggenheim reiterated a "buy" rating on shares of Centessa Pharmaceuticals in a report on Monday. TD Cowen started coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating on the stock. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $25.83.

Centessa Pharmaceuticals Trading Down 2.1 %

The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The business's 50 day moving average is $16.80 and its 200 day moving average is $15.57. The stock has a market cap of $2.32 billion, a price-to-earnings ratio of -11.52 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.05. As a group, equities analysts expect that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several large investors have recently bought and sold shares of CNTA. Mirae Asset Global Investments Co. Ltd. boosted its stake in Centessa Pharmaceuticals by 47.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company's stock valued at $40,000 after acquiring an additional 826 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Centessa Pharmaceuticals by 103.1% during the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company's stock worth $48,000 after buying an additional 1,509 shares during the period. Barclays PLC boosted its stake in shares of Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after buying an additional 4,952 shares during the period. Walleye Capital LLC acquired a new stake in shares of Centessa Pharmaceuticals during the third quarter worth about $187,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Centessa Pharmaceuticals by 99.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company's stock worth $217,000 after buying an additional 6,785 shares during the period. Institutional investors and hedge funds own 82.01% of the company's stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.